HylaPharm is a university spinout company developing new targeted cancer therapies. HylaPlat is a new cancer drug that has already shown efficacy in multiple mouse models, and in several dogs with large, naturally occurring cancers. It is the first targeted chemotherapy for potentially deadly, locally advanced cancers that affect nearly 200,000 Americans. Unlike conventional chemotherapy that enters vein and goes all over the body before getting to the tumor, HylaPlat tm is injected directly into the primary tumor, resulting in very high tumor penetration. HylaPlat tm then goes into local lymph nodes, which is where tumors generally metastasize first. HylaPlat tm works by complexing conventional chemotherapy with nano-sized Hyaluronan, a natural compound in the body that cancers seek and bind. HylaPlat tm is manufactured in university incubator space. We aim for a shortened development path because our initial target is an orphan disease, and our product is a novel complex of already approved drugs. Kansas BioScience Authority has funded our upcoming FDA Investigational New Drug-enabling animal trials. The Kansas Department of Commerce has qualified HylaPharm as a Kansas Angel company.